Patient characteristics
| Patient no. . | Sex . | Age, y . | Disease . | HLA units to patient . | HLA unit to unit . | TNC, ×107/kg . | CD34, ×105/kg . | ANC, d . | aGVHD grade . | Relapse day* . | Death day* . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 14 | AML | 5/6 and 5/6 | 4/6 | 7.9 | 4.5 | 14 | 3 | 1378 | 1471 |
| 2 | F | 21 | ALL | 4/6 and 4/6 | 3/6 | 8.1 | 3.0 | 26 | 2 | 138 | |
| 3 | F | 50 | AML | 5/6 and 4/6 | 4/6 | 5.3 | 2.4 | 19 | 2 | ||
| 4 | F | 24 | CML | 4/6 and 4/6 | 4/6 | 5.3 | 2.2 | 44 | 2 | ||
| 5 | M | 39 | AML | 4/6 and 4/6 | 3/6 | 4.8 | 2.1 | 25 | 2 | ||
| 6 | M | 62 | AML | 4/6 and 5/6 | 3/6 | 5.5 | 2.8 | 17 | 0 | 203 | 229 |
| 7 | F | 14 | AML | 5/6 and 5/6 | 4/6 | 3.8 | — | 19 | 2 | ||
| 8 | M | 10 | AML | 4/6 and 4/6 | 4/6 | 14.3 | — | 25 | 3 | ||
| 9 | M | 52 | ALL | 4/6 and 4/6 | 4/6 | 5.8 | 4.2 | 18 | 2 | ||
| 10 | M | 25 | AML | 4/6 and 4/6 | 4/6 | 3.8 | 1.4 | 36 | 2 | 410 | |
| 11 | F | 51 | AML | 5/6 and 5/6 | 4/6 | 4.2 | 1.7 | 20 | 2 | ||
| 12 | M | 13 | ALL | 5/6 and 4/6 | 3/6 | 4.6 | 2.9 | 32 | 1 | ||
| 13 | M | 42 | AML | 4/6 and 4/6 | 4/6 | 5.1 | 4.4 | 32 | 0 |
| Patient no. . | Sex . | Age, y . | Disease . | HLA units to patient . | HLA unit to unit . | TNC, ×107/kg . | CD34, ×105/kg . | ANC, d . | aGVHD grade . | Relapse day* . | Death day* . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 14 | AML | 5/6 and 5/6 | 4/6 | 7.9 | 4.5 | 14 | 3 | 1378 | 1471 |
| 2 | F | 21 | ALL | 4/6 and 4/6 | 3/6 | 8.1 | 3.0 | 26 | 2 | 138 | |
| 3 | F | 50 | AML | 5/6 and 4/6 | 4/6 | 5.3 | 2.4 | 19 | 2 | ||
| 4 | F | 24 | CML | 4/6 and 4/6 | 4/6 | 5.3 | 2.2 | 44 | 2 | ||
| 5 | M | 39 | AML | 4/6 and 4/6 | 3/6 | 4.8 | 2.1 | 25 | 2 | ||
| 6 | M | 62 | AML | 4/6 and 5/6 | 3/6 | 5.5 | 2.8 | 17 | 0 | 203 | 229 |
| 7 | F | 14 | AML | 5/6 and 5/6 | 4/6 | 3.8 | — | 19 | 2 | ||
| 8 | M | 10 | AML | 4/6 and 4/6 | 4/6 | 14.3 | — | 25 | 3 | ||
| 9 | M | 52 | ALL | 4/6 and 4/6 | 4/6 | 5.8 | 4.2 | 18 | 2 | ||
| 10 | M | 25 | AML | 4/6 and 4/6 | 4/6 | 3.8 | 1.4 | 36 | 2 | 410 | |
| 11 | F | 51 | AML | 5/6 and 5/6 | 4/6 | 4.2 | 1.7 | 20 | 2 | ||
| 12 | M | 13 | ALL | 5/6 and 4/6 | 3/6 | 4.6 | 2.9 | 32 | 1 | ||
| 13 | M | 42 | AML | 4/6 and 4/6 | 4/6 | 5.1 | 4.4 | 32 | 0 |
The day of neutrophil engraftment was defined as the first of 3 consecutive days of an ANC of ≥0.5 × 109/L or greater.
aGVHD, acute GVHD; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ANC, absolute neutrophil count; CML, chronic myelogenous leukemia; TNC, total nucleated dose.
Blank entries indicate that the event of interest did not happen in those patients.